State Street SPDR S&P Pharmaceuticals ETF
$63.61−1.19 (−1.84%)
- 0.35%
- $454M
- +28.7%
- 0.43%
- 155K sh
- low $47.60high $74.35
The ETF.net XPH Grade
B
Score 66 out of 100
- 2 of 9
Score 66 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.A79 out of 100Rank 2 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.B64 out of 100Rank 5 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.D37 out of 100Rank 7 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B61 out of 100Rank 5 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A89 out of 100Rank 1 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B69 out of 100Rank 4 of 9
Our read on XPH
In short
BMost pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.
Stated mandate
The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.
Why people hold it
Worth knowing
XPH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
XPH$12,867
Returns run to the Nov 2, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | XPH |
|---|---|
| Year to date | +13.9% |
| 1 month | 0.0% |
| 3 months | −6.5% |
| 1 year | +28.7% |
| 3 years | +21.7% |
| 5 years | +6.5% |
| 10 years | +6.0% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | XPH |
|---|---|---|
| 2026 YTD | +13.9% | |
| 2025 | +31.6% | |
| 2024 | +4.9% | |
| 2023 | +3.0% | |
| 2022 | −9.8% | |
| 2021 | −10.5% | |
| 2020 | +14.7% |
XPH in the news
XPH Dividends
- 0.43%
- $0.27
- $0.04 per share
- Quarterly
XPH Risk
- 19.3%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.95
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −30.9%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.72
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
FMP measures it over up to five years of monthly returns.
XPH Cost
Overpaying vs PBPH, cheapest in Pharma & Therapeutics
$4,400
On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.
XPH 0.35%
$7,126
PBPH 0.13% Cheapest
$2,726
Cost over time
Year by year
| Year | XPH | PBPH | Overpaying |
|---|---|---|---|
| 10 | $634 | $238 | $396 |
| 20 | $2,454 | $930 | $1,524 |
| 30 | $7,126 | $2,726 | $4,400 |
Other funds in Pharma & Therapeutics
- APPHVanEck Pharmaceutical ETFExpense ratio 0.36%1 year return +31.4%
- BIHEiShares U.S. Pharmaceuticals ETFExpense ratio 0.37%1 year return +43.0%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +35.1%
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +46.7%
